Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?

Stiekema, J.; Cats, Annemieke; Kuijpers, A.; Coevorden, Frits van; Boot, H.; Jansen, Edwin P.M.; Verheij, Marcel; Balagué, Olga; Hauptmann, Michael; Sandick, Johanna W. van

doi:10.1016/j.ejso.2013.02.026

Cited by 44 publications

(37 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to Lauren staging, GEFT protein expression was the highest in the diffuse type and lowest in the intestinal type. Several studies have demonstrated that the Lauren stage was closely associated with certain clinicopathological characteristics such as age, sex, tumor size, location, grade, invasion depth, lymphovascular invasion and prognosis of GC (36,37). Patients with intestinal type GC were predominantly older, male, had a smaller tumor size, had relatively well differentiated tumors, and tumors which has less tumor invasion depth and less lymphovascular invasion (37).…”

Section: Discussionmentioning

confidence: 99%

GEFT protein expression in digestive tract malignant tumors and its clinical significance

et al. 2019

View full text Add to dashboard Cite

Guanine nucleotide exchange factor T (GEFT), a member of the Rho guanine nucleotide exchange factor family, is expressed in a variety of tumors. In the present study, the expression and clinical significance of GEFT in malignant digestive tract tumors was assessed. Tumor and adjacent control samples from 180 patients were tested. Positive GEFT expression rates were 80, 83.33 and 86.67% in esophageal squamous carcinoma (ESCC), gastric carcinoma (GC) and colorectal cancer (CRC), respectively. GEFT expression was associated with diffuse type carcinoma according to the Lauren classification (χ 2 =12.525, P=0.002) and tumor-node-metastasis (TNM) stages III/IV (χ 2 =4.033, P=0.045) in GC, and with vessel carcinoma embolus (χ 2 =7.890, P=0.005) and lymph node metastasis (χ 2 =5.455, P=0.020) in CRC, but was not associated with other clinicopathological parameters. Patients with high levels of GEFT protein expression had a less favorable outcome compared with patients with low levels of GEFT expression in patients with CRC (χ 2 =3.876, P=0.049). However, a significant association was not found between GEFT expression and overall survival in patients with ESCC (χ 2 =0.040, P=0.842) or GC (χ 2 =0.501, P=0.479). The rate of human epidermal growth factor receptor 2 upregulation in patients with GC was 13.33% and it was associated with nerve invasion (χ 2 =4.005, P=0.045) and TNM stages III/IV (χ 2 =5.600, P=0.018). Mismatch repair protein (MMRP) defect was observed in six cases, and the KRAS mutation rate was 26.67% in patients with CRC. GEFT expression was significantly correlated with MMRP (r=-0.285, P=0.027) and KRAS mutation in patients with CRC (r=0.697, P<0.001). These findings revealed frequent GEFT upregulation in malignant digestive tract tumors, which may have promoted tumor development. GEFT expression in CRC may be associated with microsatellite instability and KRAS mutation status, suggesting that GEFT may be a potential therapeutic target for patients with CRC.

show abstract

Section: Discussionmentioning

confidence: 99%

GEFT protein expression in digestive tract malignant tumors and its clinical significance

et al. 2019

View full text Add to dashboard Cite

show abstract

“…4,10,14,19 Rannsóknir eru þó ekki allar alveg samhljóma og hafa sumar sýnt fram á faekkun í báðum hópunum. 20,21 Líkt og aðrir hafa sýnt fram á, þar með talið Laurén sjálfur, voru þeir sem greindust með dreifkrabbamein í okkar rannsókn yngri 10,22,23 og kynjahlutfallið í hópi dreifkrabbameina jafnara. 22,23 Fyrri rannsóknir hafa þegar sýnt verri lifun sjúklinga með dreifkrabbamein en þó ekki allar eftir að leiðrétt hefur verið fyrir öðrum samverkandi þáttum.…”

Section: Umraeðurunclassified

“…20,21 Líkt og aðrir hafa sýnt fram á, þar með talið Laurén sjálfur, voru þeir sem greindust með dreifkrabbamein í okkar rannsókn yngri 10,22,23 og kynjahlutfallið í hópi dreifkrabbameina jafnara. 22,23 Fyrri rannsóknir hafa þegar sýnt verri lifun sjúklinga með dreifkrabbamein en þó ekki allar eftir að leiðrétt hefur verið fyrir öðrum samverkandi þáttum. 24,25 Rannsókn okkar leiddi hins vegar í ljós marktaekan mun á lifun útfrá Laurén-flokkun eftir leiðréttingu fyrir ýmsum samverkandi þáttum, þar með talið stigi og niður-stöðu aðgerðar.…”

Section: Umraeðurunclassified

“…Rannsóknin er því samhljóma nýlegum rannsókn-um sem benda til þess að það að greinast með dreifkrabbamein samkvaemt Laurén-flokkun sé sjálfstaeður áhaettuþáttur fyrir verri horfum. 22,23,26 Talsverður hluti af meinunum var ekki stiganlegur, eða 25%, annaðhvort vegna þess að sjúkraskrárnar fundust ekki eða upplýsingarnar í sjúkraskránum voru ekki fullnaegjandi. Stigun byggir á myndgreiningu með tilliti til fjarmeinvarpa og lýsingu meinafraeðings í vefjasvörum brottnumins maga sem lýsir dýpt aexlis og því hvort meinvörp séu til staðar í eitlum.…”

Section: Umraeðurunclassified

“…22 Með-ferðarleiðbeiningar í Þýskalandi leggja til meiri fjarlaegð frá aexli til skurðbrúna ef vefjagreiningin sýnir dreifkrabbamein. 27,28 Þetta maetti eflaust skoða nánar á Íslandi í ljósi mögulega verri horfa og laegra hlutfalls dreifkrabbameina en garnafrumukrabbameina sem voru með fríar skurðbrúnir í okkar rannsókn.…”

Section: Umraeðurunclassified

See 2 more Smart Citations

Faraldsfræði tveggja Laurén-flokka kirtilfrumukrabbameina í maga á Íslandi árin 1990-2009

Ólafsdóttir¹,

Alexíusdóttir²,

Lund³

et al. 2016

LBL

View full text Add to dashboard Cite

Diagnostic and therapeutic potencies of miR‐18a‐5p in mixed‐type gastric adenocarcinoma

Wang

Zhang

Wang

et al. 2021

J of Cellular Biochemistry

View full text Add to dashboard Cite

Mixed‐type gastric adenocarcinoma (by Lauren Classification) has poor clinical outcomes with few targeted treatment options. The primary objective of this study was to find the prognostic factors, accurate treatment approaches, and effective postoperative adjuvant therapy strategies for patients with mixed‐type gastric adenocarcinoma (GA). A microRNA sequencing data set and the corresponding clinical parameters of patients with gastric cancer were obtained from The Cancer Genome Atlas. Differentially expressed microRNAs (DEMs) of diffuse‐ and intestinal‐type GA were, respectively, determined. Kaplan–Meier and log‐rank tests were subsequently carried out to evaluate the prognostic relevance of each DEM. To study the common factors between diffuse‐ and intestinal‐type GA, a pathway enrichment analysis was performed on the target genes of identified DEMs using the PANTHER database. After data preprocessing, we analyzed a total of 230 samples from 210 patients with GA. Eighty‐six DEMs in diffuse‐type GA samples and 59 DEMs in intestinal‐type GA samples were, respectively, identified (p 2.0). The Kaplan–Meier survival method further screened out six prognosis‐related DEMs for diffuse‐type GA and seven prognosis‐related DEMs for intestinal‐type GA (p < 0.05). MiR‐18a‐5p was found to be the only common prognosis‐related DEM between diffuse‐ and intestinal‐type GA. The common signaling pathways further revealed that target genes of miR‐18a‐5p are involved in mixed‐type GA progression. This study suggests that miR‐18a‐5p acts as a potential target for treatment, and common signal pathways provide a rich basis to seek reliable and effective molecular targets for the diagnosis, clinical treatment, and postoperative adjuvant therapy strategy of mixed‐type GA.

show abstract

Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?

Cited by 44 publications

References 44 publications

GEFT protein expression in digestive tract malignant tumors and its clinical significance

GEFT protein expression in digestive tract malignant tumors and its clinical significance

Faraldsfræði tveggja Laurén-flokka kirtilfrumukrabbameina í maga á Íslandi árin 1990-2009

Diagnostic and therapeutic potencies of miR‐18a‐5p in mixed‐type gastric adenocarcinoma

Contact Info

Product

Resources

About